GlassScriptPhysician profile
Gregory K Lux
NPI 1558409748
$4,237.42
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,222 · 2020: $15.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $2,938.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $277.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $79.60 | 2019 | |
| Genzyme Corporation | $67.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $62.63 | 2019 | |
| Csl Behring | $53.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.31 | 2019 | |
| Kaleo, INC. | $46.58 | 2019 | |
| Genentech USA, INC. | $44.30 | 2019 | |
| Grifols USA, LLC | $30.89 | 2019 | |
| Pfizer INC. | $25.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.